Combination of PARP inhibitor and CDK4 /6 inhibitor modulates cGAS / STING‐ dependent therapy‐induce...
Combination of PARP inhibitor and CDK4 /6 inhibitor modulates cGAS / STING‐ dependent therapy‐induced senescence and provides “one‐two punch” opportunity with anti‐PD‐L1 therapy in colorectal cancer
About this item
Full title
Author / Creator
Wang, Tao , Liu, Weizhen , Shen, Qian , Tao, Ruikang , Li, Chengguo , Shen, Qian , Lin, Yao , Huang, Yongzhou , Yang, Lei , Xie, Gengchen , Bai, Jie , Li, Ruidong , Wang, Lulu , Tao, Kaixiong and Yin, Yuping
Publisher
Tokyo: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
Tokyo: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Although PARP inhibitor (PARPi) has been proven to be a promising anticancer drug in cancer patients harboring BRCA1/2 mutation, it provides limited clinical benefit in colorectal cancer patients with a low prevalence of BRCA1/2 mutations. In our study, we found PARPi talazoparib significantly induced cellular senescence via inhibiting p53 ubiquiti...
Alternative Titles
Full title
Combination of PARP inhibitor and CDK4 /6 inhibitor modulates cGAS / STING‐ dependent therapy‐induced senescence and provides “one‐two punch” opportunity with anti‐PD‐L1 therapy in colorectal cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10637067
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10637067
Other Identifiers
ISSN
1347-9032
E-ISSN
1349-7006
DOI
10.1111/cas.15961
